BI-3406 is an Orally Active and Selective KRAS and SOS1 Interaction Inhibitor
KRAS functions as a molecular switch, cycling between inactive (GDP-bound) and active (GTP-bound) states to transduce extracellular signals via cell-surface receptors. KRAS signaling occurs through engagement with effector proteins that orchestrate intracellular signaling cascades regulating tumor cell survival and proliferation. Mutations in the KRAS gene occur in approximately one of seven...
BAY-293 is a Selective KRas-SOS1 Inhibitor for RAS-Driven Tumors Treatment
Members of the RAS family of GTPases (which comprises KRAS, NRAS, and HRAS) are major oncogenes. Especially, mutations in the RAS genes are major oncogenes with a high occurrence rate in human cancers. RAS-RAF-MEK-ERK and RAS-PI3K-PDK1-AKT pathways are essential to cell survival and proliferation. SOS1 is also the guanine...